Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring

Journal of Clinical Oncology

Volumn 24, Issue 27, 2006, Pages 4507-4514

  Mileshkin, Linda ^a   Stark, Richard ^a   Day, Bruce ^a   Seymour, John F ^a   Zeldis, Jerome B ^a   Prince, H Miles ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; THALIDOMIDE; VINCRISTINE; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; HUMAN; MAJOR CLINICAL STUDY; MYELOMA; NEUROPATHY; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEMALE; MALE; MIDDLE AGED; MONITORING; MULTICENTER STUDY; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME;

AGED; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THALIDOMIDE; TIME FACTORS;

EID: 33749051832     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.6689     Document Type: Article

References (37)

1. Hideshima T, Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927-937, 2002
2. Singhal S, Mehta J: Thalidomide in cancer: Potential uses and limitations. BioDrugs 15:163-172, 2001
3. Cavaletti G, Bogliun G, Marzorati L, et al: Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 14:1287-1292, 1994
4. Mileshkin L, Antil Y, Rischin D: Management of complications of chemotherapy, in Gershenson DM, McGuire MP, Gore M, et al (eds): Gynaecologic Cancer: Controversies in Management. Philadelphia, PA, Elsevier Science, 2002
5. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
6. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
7. Umapathi T, Chaudhry V: Toxic neuropathy. Curr Opin Neurol 18:574-580, 2005
8. Cavaletti G, Beronio A, Reni L, et al: Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study. Neurology 62:2291-2293, 2004
9. Rajkumar SV, Gertz MA, Kyle, RA, et al: Thalidomide-induced neuropathy. Mayo Clin Proc 77:1391-1396, 2002
10. Bastuji-Garin S, Ochonisky S, Bouche P, et al: Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients. J Invest Dermatol 119:1020-1026, 2002
11. Briani C, Zara G, Rondinone R, et al: Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus. Neurology 62:2288-2290, 2004
12. Chaudhry V, Cornblath DR, Corse A, et al: Thalidomide-induced neuropathy. Neurology 59:1872-1875, 2002
13. Fullerton PM, O'Sullivan DJ: Thalidomide neuropathy: A clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 31:543-551, 1968
14. Gardner-Medwin JM, Smith NJ, Powell RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53:828-832, 1994
15. Harland CC, Steventon GB, Marsden JR: Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 49:1-6, 1995
16. Hess CW, Hunziker T, Kupfer A, et al: Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 233:83-89, 1986
17. Lagueny A, Rommel A, Vignolly B, et al: Thalidomide neuropathy: An electrophysiologic study. Muscle Nerve 9:837-844, 1986
18. Maurer T, Poncelet A, Berger T: Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: Efficacy and risk of neuropathy. Arch Dermatol 140:845-849, 2004
19. Molloy FM, Floeter MK, Syed NA, et al: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 24:1050-1057, 2001
20. Ochonisky S, Verroust J, Bastuji-Garin S, et al: Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 130:66-69, 1994
21. Offidani M, Corvatta L, Marconi M, et al: Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 72:403-409, 2004
22. Tosi P, Zamagni E, Cellini C, et al: Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 74:212-216, 2005
23. Sheskin J: The treatment of lepra reaction in lepromatous leprosy: Fifteen years' experience with thalidomide. Int J Dermatol 19:318-322, 1980
24. Aronson IK, Yu R, West DP, et al: Thalidomide-induced peripheral neuropathy: Effect of serum factor on nerve cultures. Arch Dermatol 120:1466-1470, 1984
25. Clemmensen OJ, Olsen PZ, Andersen KE: Thalidomide neurotoxicity. Arch Dermatol 120:338-341, 1984
26. Wulff CH, Hoyer H, Asboe-Hansen G, et al: Development of polyneuropathy during thalidomide therapy. Br J Dermatol 112:475-480, 1985
27. Giannini F, Volpi N, Rossi S, et al: Thalidomide-induced neuropathy: A ganglionopathy? Neurology 60:877-878, 2003
28. Apfel SC, Zochodne DW: Thalidomide neuropathy: Too much or too long? Neurology 62:2158-2159, 2004
29. Mileshkin L, Biagi JJ, Mitchell P, et al: Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: Adverse prognostic impact of advanced age. Blood 102:69-77, 2003
30. Ghobrial IM, Rajkumar SV: Management of thalidomide toxicity. J Support Oncol 1:194-205, 2003
31. Richardson P, Schlossman R, Jagannath S, et al: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79:875-882, 2004
32. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
33. Neben K, Moehler T, Benner A, et al: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377-3382, 2002
34. Johnston RE, Abdalla SH: Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 43:351-354, 2002
35. Pini M, Baraldi A, Pietrasanta D, et al: Low-dose of thalidomide in the treatment of refractory myeloma. Haematologica 85:1111-1112, 2000
36. Palumbo A, Giaccone L, Bertola A, et al: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403, 2001
37. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006